SCHEMBL18149209

SCHEMBL18149209

CN(N)C(=O)c1cc(F)c(Cl)nc1Cl

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.59
NFE2L2 Q16236 1/20 0.59
CNR1 P21554 1/20 0.35
ALPL P05186 1/20 0.34
CASP1 P29466 2/20 0.33
DHODH Q02127 3/20 0.32
CTNNB1 P35222 1/20 0.32
TCF7L2 Q9NQB0 1/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 2/20 0.32
APEX1 P27695 1/20 0.32
ATF1 P18846 1/20 0.31
NFKB1 P19838 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
CYP2C19 P33261 1/20 0.30
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2920688 0.86 KEAP1 (0.62) KEAP1NFE2L2CNR1ALPLCTNNB1
SCHEMBL14395311 0.81 KEAP1 (0.56) KEAP1NFE2L2CNR1ALPLMEN1
SCHEMBL4841196 0.79 KEAP1 (0.57) KEAP1NFE2L2ALPLALDH1A1POLB
SCHEMBL12773832 0.78 KEAP1 (0.53) KEAP1NFE2L2CNR1ALPLCTNNB1
SCHEMBL20788869 0.78 KEAP1 (0.66) KEAP1NFE2L2CASP1DHODHCTNNB1
SCHEMBL166218 0.77 KEAP1 (0.69) KEAP1NFE2L2CASP1POLB
SCHEMBL30474526 0.77 KEAP1 (0.69) KEAP1NFE2L2CASP1POLB
SCHEMBL10518552 0.77 KEAP1 (0.69) KEAP1NFE2L2CASP1CTNNB1TCF7L2
SCHEMBL113812 0.74 KEAP1 (1.00) KEAP1NFE2L2ALPLCASP1DHODH
SCHEMBL31048928 0.74 KEAP1 (0.71) KEAP1NFE2L2CASP1CTNNB1TCF7L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10160748-B2 Indazolones as modulators of tnf signaling ABBVIE INC. (US) 2018-12-25 US disclosed
US-20180086737-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-03-29 US disclosed
EP-3294726-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-21 EP disclosed
WO-2016168633-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 WO disclosed
US-20160304496-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304496-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, CD40, TNFRSF1A KEAP1 2397/4885NFE2L2 711/4885CNR1 2578/4885
US-20180086737-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, CD40, TNFRSF1A KEAP1 2397/4885NFE2L2 711/4885CNR1 2578/4885
US-10160748-B2 Indazolones as modulators of tnf signaling TNF, CD40, TNFRSF1A KEAP1 2397/4885NFE2L2 711/4885CNR1 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.